| HWM |
Report |
Revenue |
BEAT |
pred ~$2.46B vs. cons $2.43B |
MEDIUM |
| HWM |
Report |
Adjusted EBITDA |
BEAT |
pred ~$788M vs. cons $775M |
MEDIUM |
| HWM |
Report |
Adjusted EPS |
BEAT |
pred ~$1.27 vs. cons $1.24 |
MEDIUM |
| HWM |
Guide |
Revenue |
BETTER |
guide ~$2.49B vs. cons $2.47B (2026Q3) |
MEDIUM |
| HWM |
Guide |
Adjusted EPS |
BETTER |
guide ~$1.29 vs. cons $1.26 (2026Q3) |
MEDIUM |
| HWM |
Guide |
Revenue |
BETTER |
guide ~$9.82B vs. cons $9.74B (FY2026) |
MEDIUM |
| HWM |
Guide |
Adjusted EBITDA |
BETTER |
guide ~$3.17B vs. cons $3.13B (FY2026) |
MEDIUM |
| HWM |
Guide |
Adjusted EPS |
BETTER |
guide ~$5.12 vs. cons $5.05 (FY2026) |
MEDIUM |
| HWM |
Guide |
Free Cash Flow |
BETTER |
guide ~$1.85B vs. cons $1.78B (FY2026) |
LOW |
| HWM |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.2% |
— |
LOW |
| HWM |
Return |
5-day cumulative residual |
+4.3% (FOLLOW-THROUGH) |
FY2026 guide of ~$5.12 EPS vs. $5.05 consensus implies roughly $2.63 of second-half EPS after predicted first-half EPS of $2.49, versus approximately $2.59 embedded by consensus; positive out-period revisions should outweigh valuation-driven profit-taking. |
LOW |